Novocure stock advanced Wednesday morning — but pulled back from more massive gains — after the Food and Drug Administration ...

Novocure (NASDAQ:NVCR) has reported preliminary revenues of $605.2M for 2024, higher than the consensus estimate of $596.95M. For the fourth quarter, the oncology company issued preliminary ...

NovoCure (NVCR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on the stock and ...

Cancer-targeting biotech NovoCure (NASDAQ: NVCR) had some highly positive news from the laboratory to deliver earlier this week, and investors couldn't grab hold of the stock fast enough.

From the beginning of 2024 through Dec. 3, shares of Novocure rose 112% higher. They've been soaring because, in addition to positive pancreatic cancer results, its Optune Lua device earned ...

Novocure is seeking regulatory approval in the US, EU, Japan and other key markets after the Phase III PANOVA-3 pancreatic cancer study met its endpoints. The PANOVA-3 study (NCT03377491) met its ...

Novocure to present at the 43rd Annual J.P. Morgan Healthcare Conference at 9:00 a.m. PST on Wednesday, January 15, 2025 Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial and ...

TTFields therapy was well-tolerated, and safety was consistent with prior clinical studies. Novocure plans to file for regulatory approval in the U.S., EU, Japan and other key markets. Zai Lab ...